Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS & SPR verified)

• Background:

  NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.

• Description:

  Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (HL1-H82E4) is expressed from human 293 cells (HEK293) . It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQV) .

• Specifications:

  Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.3 kDa and 13.8 kDa. The protein migrates as 42-45 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

• Accession Number:

  AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQV

• Expression Region:

  Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide

• Host:

  HEK293

• Target:

  HLA-A*02:01 & B2M & NY-ESO-1

• Conjugation:

  Biotin-labeled

• Tag:

  C-10xHis & C-Avi

• Source:

  Human

• Stability:

  ● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

• Endotoxin:

  1.0 EU per μg

• Purity:

  95%

• Bioactivity:

  Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Cat. No. HL1-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.2-16 ng/mL (QC tested).

• Format:

  Powder

• Buffer:

  PBS, pH7.4

• Additives:

  Trehalose

• Molecular Weight:

  36.3 kDa and 13.8 kDa

• Shipping Conditions:

  RT

• Storage Conditions:

  -20°C

• Package Size:

  200ug*1

• Species:

  Human